KEYTRUDA QLEX

pembrolizumab and berahyaluronidase alfa-pmph · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for KEYTRUDA QLEX, covering 2025-09-19 to 2026-07-31. Get the full timeline:

Most recent: FDA Approved: KEYTRUDA QLEX — Supplemental Application (Merck Sharp & Dohme LLC)